Paper32611684
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.
Jiang Q and 12 others. Sci Transl Med, 2020. Cited by 46 papers, by iCite.
Cite this record
ConductScience Library. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Papers, record 32611684. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32611684
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunotoxins | Major topic |
| Lung Neoplasms | Major topic |
| Mesothelioma | Major topic |
| Animals | |
| B7-H1 Antigen | |
| CD8-Positive T-Lymphocytes | |
| GPI-Linked Proteins | |
| Humans | |
| Immunoconjugates | |
| Leukocytes, Mononuclear | |
| Mesothelin | |
| Mice | |
| Prospective Studies |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Z01 BC010020 | Intramural NIH HHS | United States | Z01BC010020 | PubMed | NIH RePORTER |
| Z01 BC010816 | Intramural NIH HHS | United States | ZIABC010816 | PubMed and NIH | NIH RePORTER |
| Z01 SC007202 | Intramural NIH HHS | United States | Z01SC007202 | PubMed | NIH RePORTER |
| ZIA BC010816 | Intramural NIH HHS | United States | ZIABC010816 | PubMed and NIH | NIH RePORTER |
| ZIABC008753 | NIH | NIH RePORTER | |||
| ZIABC011652 | NIH | NIH RePORTER | |||
| ZIDBC011540 | NIH | NIH RePORTER | |||
| ZIEBC011653 | NIH | NIH RePORTER |
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30931305 | Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma. | Front Med (Lausanne) | 2019 | https://conductscience.org/library/papers/30931305 | PubMed |
| 2 | 30441807 | SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors. | Toxins (Basel) | 2018 | https://conductscience.org/library/papers/30441807 | PubMed |
| 3 | 28729154 | Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28729154 | PubMed |
| 4 | 25348003 | Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. | Nat Commun | 2014 | https://conductscience.org/library/papers/25348003 | PubMed |
| 5 | 27863199 | Mesothelin Immunotherapy for Cancer: Ready for Prime Time? | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27863199 | PubMed |
| 6 | 22850877 | ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. | J Clin Invest | 2012 | https://conductscience.org/library/papers/22850877 | PubMed |
| 7 | 12860938 | Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12860938 | PubMed |
| 8 | 29958801 | Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. | Immunity | 2018 | https://conductscience.org/library/papers/29958801 | PubMed |
| 9 | 1351045 | Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. | Int J Cancer | 1992 | https://conductscience.org/library/papers/1351045 | PubMed |
| 10 | 28878676 | PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. | Front Pharmacol | 2017 | https://conductscience.org/library/papers/28878676 | PubMed |
| 11 | 24824231 | Discovery of mesothelin and exploiting it as a target for immunotherapy. | Cancer Res | 2014 | https://conductscience.org/library/papers/24824231 | PubMed |
| 12 | 18771959 | Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. | Clin Immunol | 2008 | https://conductscience.org/library/papers/18771959 | PubMed |
| 13 | 26463707 | New Life for Immunotoxin Cancer Therapy. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26463707 | PubMed |
| 14 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 15 | 10778980 | Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. | Clin Cancer Res | 2000 | https://conductscience.org/library/papers/10778980 | PubMed |
| 16 | 26719230 | Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. | Lancet | 2016 | https://conductscience.org/library/papers/26719230 | PubMed |
| 17 | 28650338 | IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. | J Clin Invest | 2017 | https://conductscience.org/library/papers/28650338 | PubMed |
| 18 | 28291584 | Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28291584 | PubMed |
| 19 | 30244849 | Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. | J Thorac Oncol | 2018 | https://conductscience.org/library/papers/30244849 | PubMed |
| 20 | 24321581 | Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. | Lung Cancer | 2014 | https://conductscience.org/library/papers/24321581 | PubMed |
Cited by38
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41425223 | Mapping drug distribution using CT imaging following direct tissue injection in ex vivo liver: informing clinical implementation. | CVIR Oncol | 2025 | https://conductscience.org/library/papers/41425223 | PubMed |
| 41400642 | Novel perspectives on MSLN-targeted cancer therapy: from molecular mechanisms to clinical translation. | Cancer Biol Ther | 2025 | https://conductscience.org/library/papers/41400642 | PubMed |
| 41335396 | Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations. | Mol Biomed | 2025 | https://conductscience.org/library/papers/41335396 | PubMed |
| 40682047 | Rapid diagnostic imaging and targeted immunotoxin delivery in aggressive prostate cancer using CEACAM5-specific nanobodies. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/40682047 | PubMed |
| 40679256 | Hyponatremia predicts immunotherapy resistance in biliary tract cancer. | Hum Vaccin Immunother | 2025 | https://conductscience.org/library/papers/40679256 | PubMed |
| 40506494 | [Recent Advances in Medical Treatment of Malignant Pleural Mesothelioma]. | Zhongguo Fei Ai Za Zhi | 2025 | https://conductscience.org/library/papers/40506494 | PubMed |
| 40406146 | A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTEFAP5/CD3, CAR-T cells, and immunotoxins in hepatocellular carcinoma. | Front Immunol | 2025 | https://conductscience.org/library/papers/40406146 | PubMed |
| 40315330 | Robust differentiation of NK cells from MSLN.CAR-IL-15-engineered human iPSCs with enhanced antitumor efficacy against solid tumors. | Sci Adv | 2025 | https://conductscience.org/library/papers/40315330 | PubMed |
| 40135833 | GRP78 Nanobody-Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40135833 | PubMed |
| 40010770 | Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/40010770 | PubMed |
| 39981134 | Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics. | Immunooncol Technol | 2025 | https://conductscience.org/library/papers/39981134 | PubMed |
| 38893092 | Targeted Therapy in Mesotheliomas: Uphill All the Way. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38893092 | PubMed |
| 38706610 | Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers. | Front Oncol | 2024 | https://conductscience.org/library/papers/38706610 | PubMed |
| 38610930 | Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38610930 | PubMed |
| 38052492 | Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with Pseudomonas Exotoxin Catalytic Domain for Cancer Therapeutics. | Mol Cells | 2023 | https://conductscience.org/library/papers/38052492 | PubMed |
| 37992257 | Targeted Approaches to Treatment of Pleural Mesothelioma: A Review. | JCO Precis Oncol | 2023 | https://conductscience.org/library/papers/37992257 | PubMed |
| 37869242 | Biology of Mesothelin and Clinical Implications: A Review of Existing Literature. | World J Oncol | 2023 | https://conductscience.org/library/papers/37869242 | PubMed |
| 37146241 | NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors. | Eur J Immunol | 2023 | https://conductscience.org/library/papers/37146241 | PubMed |
| 36763234 | Targeting Mesothelin in Solid Tumours: Anti-mesothelin Antibody and Drug Conjugates. | Curr Oncol Rep | 2023 | https://conductscience.org/library/papers/36763234 | PubMed |
| 36669143 | Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma. | Cancer Discov | 2023 | https://conductscience.org/library/papers/36669143 | PubMed |
Genes22
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32611684
GET https://conductscience.org/api/papers/v1/32611684/references?page=2